In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors-Reference-Cited by-同舟云学术

In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors

Published:2008-04 Issue:4 Volume:52 Page:1545-1548
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Desbois Delphine¹,Roquebert Bénédicte¹,Peytavin Gilles²,Damond Florence¹,Collin Gilles¹,Bénard Antoine³,Campa Pauline⁴,Matheron Sophie⁵,Chêne Geneviève³,Brun-Vézinet Françoise¹,Descamps Diane¹

Affiliation:

1. Laboratoire de Virologie, Service de Microbiologie, Hôpital Bichat-Claude Bernard, Paris, France

2. Laboratoire de Toxicologie, Service de Pharmacie, Hôpital Bichat-Claude Bernard, Paris, France

3. ISPED, Université Victor Segalen Bordeaux 2, INSERM U593, Bordeaux, France

4. Service de Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, Paris, France

5. Service de Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, Paris, France

Abstract

ABSTRACT We determine phenotypic susceptibility of human immunodeficiency virus type 2 (HIV-2) isolates to amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, saquinavir, and tipranavir. Saquinavir, lopinavir, and darunavir are potent against wild-type HIV-2 isolates and should be preferred as first-line options for HIV-2-infected patients. Other protease inhibitors are less active against HIV-2 than against HIV-1.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01284-07

Reference17 articles.

1. Adjé-Touré, C. A., R. Cheingsong, J. G. Garcia-Lerma, S. Eholie, M. Borget, J. Bouchez, R. A. Otten, C. Maurice, M. Sassan-Morokro, R. E. Ekpini, M. Nolan, T. Chorba, W. Heneine, and J. N. Nkengasong. 2003. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS17:S49-S54.

2. Polymorphism and drug-selected mutations in the reverse transcriptase of HIV-2 from patients living in southern France 2003

3. Polymorphism of the Human Immunodeficiency Virus Type 2 (HIV-2) Protease Gene and Selection of Drug Resistance Mutations in HIV-2-Infected Patients Treated with Protease Inhibitors

4. Damond, F., G. Collin, S. Matheron, G. Peytavin, P. Campa, S. Delarue, A. Taieb, A. Benard, G. Chene, F. Brun-Vezinet, and D. Descamps. 2005. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene. Antivir. Ther.10:861-865. (Letter.)

5. Binding kinetics of PI to wild type and multi drug resistant HIV-1 proteases: a mechanistic study of the genetic barrier to resistance to darunavir 2007

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Outcomes of Integrase Strand Transfer Inhibitors Containing Antiretroviral Therapy in HIV-2: A Narrative Review;Infectious Diseases and Therapy;2024-05-09

2. Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds;International Journal of Molecular Sciences;2023-03-21

3. High Instantaneous Inhibitory Potential of Bictegravir and the New Spiro-β-Lactam BSS-730A for HIV-2 Isolates from RAL-Naïve and RAL-Failing Patients;International Journal of Molecular Sciences;2022-11-18

4. Genetic Diversity and Low Therapeutic Impact of Variant-Specific Markers in HIV-1 Pol Proteins;Frontiers in Microbiology;2022-07-14

5. British HIV Association guidelines for the management of HIV‐2 2021;HIV Medicine;2021-12